Key takeaways
Atomoxetine (Strattera) and methylphenidate extended-release (ER) (Concerta) are both used to treat attention-deficit hyperactivity disorder (ADHD), but they have some key differences. Atomoxetine is a selective norepinephrine reuptake inhibitor (NRI) and is not a controlled substance, meaning it has a lower risk of misuse and dependence. In contrast, methylphenidate ER is a stimulant and a Schedule II controlled substance, which means it has a higher potential for misuse and dependency. Atomoxetine can take a few weeks to show full effects, while methylphenidate ER can start working within 2 hours and lasts throughout the day. Atomoxetine is available only as capsules, whereas methylphenidate ER comes in various forms, including tablets, capsules, chewable tablets, and liquid. Both medications have serious side effects, but atomoxetine has additional risks like liver damage and suicidal thoughts, while methylphenidate ER can cause serotonin syndrome and Raynaud's phenomenon. Lastly, atomoxetine is not considered a first-choice option for ADHD, whereas methylphenidate ER is often a first-choice medication.
